SCHEMBL5489083

SCHEMBL5489083

Nc1ncc2cccnc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.42
ALDH1A1 P00352 3/20 0.41
FGFR1 P11362 3/20 0.41
HSP90AA1 P07900 4/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
SRC P12931 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DHFR P00374 1/20 0.40
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSP90AB1 P08238 2/20 0.39
CASP1 P29466 1/20 0.39
ATM Q13315 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GMNN O75496 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29536760 1.00 NUDT1 (0.42) NUDT1ALDH1A1FGFR1HSP90AA1KDM4E
SCHEMBL2408295 0.74 RPS6KA5 (0.41) ALDH1A1HSP90AA1KDM4ELMNAMEN1
SCHEMBL4143004 0.74 ALDH1A1 (0.41) ALDH1A1HSP90AA1KDM4ELMNAMEN1
SCHEMBL22479754 0.74 ALDH1A1 (0.41) NUDT1ALDH1A1HSP90AA1KDM4ELMNA
SCHEMBL29808133 0.74 ALDH1A1 (0.41) ALDH1A1HSP90AA1KDM4ELMNAMEN1
SCHEMBL5794086 0.74 PSMD14 (0.42) NUDT1ALDH1A1HSP90AA1KDM4ELMNA
SCHEMBL3001006 0.74 KDM4E (0.44) ALDH1A1HSP90AA1KDM4ELMNAMEN1
SCHEMBL10369050 0.74 LMNA (0.61) ALDH1A1HSP90AA1KDM4ELMNADHFR
SCHEMBL7027758 0.72 DYRK1A (0.57) ALDH1A1HSP90AA1KDM4EMEN1KMT2A
SCHEMBL2319759 0.71 FGFR1 (0.42) ALDH1A1FGFR1SRCDHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114573581-B 5-substituted amino-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof 沈阳药科大学 2023-09-01 CN claimed
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2026-02-10 US disclosed
EP-4612149-A1 PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Cancer Research Technology Limited (GB) 2025-09-10 EP disclosed
WO-2024094962-A1 PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-05-10 WO disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 EP disclosed
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-12-06 US disclosed
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 WO disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO disclosed
US-4826528-A PLANT GROWTH REGULATORS CELAMERCK GMBH & CO. KG. (DE) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds CBR1, CBR3, COX6C NUDT1 1021/4885ALDH1A1 3360/4885FGFR1 3343/4885
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 NUDT1 1900/4885ALDH1A1 748/4885FGFR1 1/4885
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds P2RX5, PNPO, P2RX3 NUDT1 50/4885ALDH1A1 3590/4885FGFR1 3997/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 NUDT1 1019/4885ALDH1A1 1563/4885FGFR1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.